Palliative Medicine
December 18, 2025
Rita S. Matos, A. C. Silva, Licínio Rego et al.
1 citation
Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, questions arise about how to provide patients with good end-of-life care. There has been increasing interest in the beneficial effects of using psilocybin-assisted therapy in patients with severe chronic illnesses near the end of their lives and who...
General Hospital Psychiatry
December 9, 2025
Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales et al.
4 citations
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental health conditions, notably depression, loneliness, and existential distress. Traditional pharmacological treatments often exhibit limited efficacy and poor tolerability in older patients, primarily due to age-related physiological changes and the...
Progress in Palliative Care
December 1, 2025
M. Barimbing, D. Jeger, Made Edwin Sridana
ABSTRACT This narrative review synthesized the use of psilocybin-assisted therapy as a promising treatment for alleviating death anxiety in terminally ill patients. The insights presented are derived from findings reported in previous studies. Therefore, this review aimed to assess the efficacy, pharmacology, and mechanisms by which psilocybin alters brain function by affecting 5-HT2A receptors...
Research Square
December 1, 2025
Albert Buchard, Federico Seragnoli, Michel Sabé et al.
preprint
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with baseline depression and anxiety. This study characterized EMS in 192 adults and longitudinally followed 74 patients receiving psilocybin- or LSD-assisted therapy. We found that baseline schema burden, particularly related to failure and defectiveness,...
medRxiv
November 17, 2025
Georgia Ioakimidis-Macdougall, John Gardner, Paul Liknaitzky
preprint
Abstract First-hand experience with psychedelics may help clinicians develop skills and knowledge needed to work with the profound changes to conscious awareness occasioned by psychedelics. However, the topic remains contentious and underexplored. In this world-first study, we investigated the utility of psilocybin experiential therapist training in a sample of 14 mental healthcare...
November 16, 2025
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Journal of Humanistic Psychology
November 10, 2025
Robin J Murphy, Mia Wardlaw, Thomas A. Smith et al.
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have been published regarding the experiences of microdosers, but never in the context of a randomised controlled trial. Semi-structured video interviews with 40 healthy males were conducted following a double-blind placebo-controlled trial of 10 µg of...
Psychedelics
October 28, 2025
James J Gattuso, Bilgenur Bezcioglu, Carey Wilson et al.
1 citation
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behaviours with attention to translational...
University of Southern Denmark Research Portal (University of Southern Denmark)
September 9, 2025
Jacob Cohen
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD) og social angstlidelse (SAD), er meget udbredte og reagerer ofte dårligt på konventionel farmakologisk behandling og psykoterapi. Nyere kliniske forsøg har vist, at psykedeliske stoffer og ketamin kan udøve hurtige og vedvarende effekter gennem...
Acta Neuropsychiatrica
September 3, 2025
Filipe Reis Teodoro Andrade, Tobias Buchborn, Gabriel Thalheimer et al.
3 citations
Abstract Background: Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression. It primarily acts through the serotonin 5-HT2A receptor but interacts with 5-HT1A and 5-HT2C receptors....